Document is current
Any future updates will be listed below
-
Authors
Hendricks, Rachel M. https://orcid.org/0000-0001-5248-1270
Kim, Jung https://orcid.org/0000-0001-6274-2841
Haley, Jeremy S. https://orcid.org/0000-0002-3279-7873
Ramos, Mark Louie
Mirshahi, Uyenlinh L.
Carey, David J.
Stewart, Douglas R. https://orcid.org/0000-0001-8193-1488
McReynolds, Lisa J. https://orcid.org/0000-0002-1018-1453
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (Intramural Research Program, Intramural Research Program, Intramural Research Program, Intramural Research Program, Intramural Research Program)
Geisinger Health System Foundation (NA)
Regeneron Pharmaceuticals (NA)
- License Information
-
More Information
Article History
Received: 22 July 2024
Revised: 30 September 2024
Accepted: 2 October 2024
First Online: 6 November 2024
Competing interests
: The authors declare no conflict of interest. DJ Carey is the principal investigator or co-investigator and draws partial salary support for three studies funded by Regeneron Pharmaceuticals to Geisinger Clinic. One of these supports the enrollment of patients into the MyCode biobank and exome sequencing; the others are studies of individuals with genetic variants associated with clonal hematopoiesis of indeterminate potential and GAA deficiency (Pompe disease). R Hendricks, J Kim, ML Ramos, DR Stewart and LJ McReynolds’ work has been funded by the Intramural Research Program of the National Cancer Institute. JS Haley, UL Mirshahi and DJ Carey’s work is funded by Geisinger Medical Center.
